Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
:
LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, Sector 
18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report 
Test Name
Results
Units
Bio. Ref. Interval
SWASTHFIT SUPER 4
LIVER & KIDNEY PANEL, SERUM
1.00
Creatinine
(Modified Jaffe,Kinetic)
 0.70 - 1.30 
mg/dL
107
GFR Estimated
(CKD EPI Equation 2021)
 >59 
mL/min/1.73m2
G1
GFR Category
(KDIGO Guideline 2012)
  
40.00
Urea
(Urease UV)
 13.00 - 43.00 
mg/dL
18.68
Urea Nitrogen  Blood
(Calculated)
 6.00 - 20.00 
mg/dL
19
BUN/Creatinine Ratio
(Calculated)
  
7.00
Uric Acid
(Uricase)
 3.50 - 7.20 
mg/dL
30.0
AST (SGOT)
(IFCC without P5P)
 15.00 - 40.00 
U/L
40.0
ALT (SGPT)
(IFCC without P5P)
 10.00 - 49.00 
U/L
50.0
GGTP
(IFCC)
 0 - 73 
U/L
100.00
Alkaline Phosphatase (ALP)
(IFCC-AMP)
 30.00 - 120.00 
U/L
1.00
Bilirubin  Total
(Oxidation)
 0.30 - 1.20 
mg/dL
0.20
Bilirubin  Direct
(Oxidation)
 <0.3 
mg/dL
0.80
Bilirubin  Indirect
(Calculated)
 <1.10 
mg/dL
8.00
Total Protein
(Biuret)
 5.70 - 8.20 
g/dL
4.00
Albumin
(BCG)
 3.20 - 4.80 
g/dL
1.00
A : G Ratio
(Calculated)
 0.90 - 2.00 
4.00
Globulin(Calculated)
 2.0 - 3.5 
gm/dL
9.00
Calcium, Total
(Arsenazo III)
 8.70 - 10.40 
mg/dL
*WM17SPF*
Page 1 of 7
Sample Report
Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
:
LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, Sector 
18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report 
Test Name
Results
Units
Bio. Ref. Interval
4.00
Phosphorus
(Molybdate UV)
 2.40 - 5.10 
mg/dL
140.00
Sodium
(Indirect ISE)
 136.00 - 145.00 
mEq/L
4.00
Potassium
(Indirect ISE)
 3.50 - 5.10 
mEq/L
100.00
Chloride
(Indirect ISE)
 98.00 - 107.00 
mEq/L
LIPID SCREEN, SERUM
100.00
Cholesterol, Total
(CHO-POD)
 <200.00 
mg/dL
100.00
Triglycerides
(GPO-POD)
 <150.00 
mg/dL
30.00
HDL  Cholesterol
(Enz Immunoinhibition)
 >40.00 
mg/dL
50.00
LDL Cholesterol, Calculated
(Calculated)
 <100.00 
mg/dL
20.00
VLDL Cholesterol,Calculated
(Calculated)
 <30.00 
mg/dL
70
Non-HDL Cholesterol
(Calculated)
 <130 
mg/dL
Note
1.
Measurements in the same patient can show physiological & analytical variations. Three serial
 samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
2.
Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered  
among patients with moderate risk for ASCVD for risk refinement.
Treatment Goals as per Lipid Association of India 2020
 --------------------------------------------------------------------------------------------
|   RISK     |              TREATMENT GOAL             |             CONSIDER THERAPY        |
| CATEGORY   |-----------------------------------------|-------------------------------------|
|            | LDL CHOLESTEROL    | NON HDL CHLOESTEROL| LDL CHOLESTEROL| NON HDL CHLOESTEROL|
|            |  (LDL-C)(mg/dL)    | (NON HDL-C) (mg/dL)| (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)|
|------------|--------------------|--------------------|----------------|--------------------|
| Extreme    |       <50          |        <80         |                |                    |
| Risk Group |(Optional goal ≤30) |(Optional goal ≤60) |      ≥50       |        ≥80         |
| Category A |                    |                    |                |                    |
|------------|--------------------|--------------------|----------------|--------------------|
| Extreme    |                    |                    |                |                    |
| Risk Group |       ≤30          |        ≤60         |      >30       |        >60         |
| Category A |                    |                    |                |                    |
|------------|--------------------|--------------------|----------------|--------------------|
|   Very     |       <50          |        <80         |      ≥50       |        ≥80         |
|   High     |                    |                    |                |                    |
*WM17SPF*
Page 2 of 7
Sample Report
Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
:
LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, Sector 
18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report 
Test Name
Results
Units
Bio. Ref. Interval
|------------|--------------------|--------------------|----------------|--------------------|
|   High     |       <70          |        <100        |      ≥70       |        ≥100        |
|------------|--------------------|--------------------|----------------|--------------------|
| Moderate   |       <100         |        <130        |      ≥100      |        ≥130        |
|------------|--------------------|--------------------|----------------|--------------------|
|    Low     |       <100         |        <130        |      ≥130*     |        ≥160*       |
 --------------------------------------------------------------------------------------------
  *In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months
GLUCOSE, FASTING (F)
80.00
Glucose Fasting
(Hexokinase)
 70 - 100 
mg/dL
VITAMIN B12; CYANOCOBALAMIN
(CLIA)
400.00
Vitamin B12; Cyanocobalamin
 211.00 - 911.00 
pg/mL
VITAMIN D, 25 - HYDROXY, SERUM
(CLIA)
150.00
Vitamin D, 25 Hydroxy
 75.00 - 250.00 
nmol/L
Interpretation 
 --------------------------------------------------------------------------------------------
| LEVEL         | REFERENCE RANGE IN nmol/L| COMMENTS                                        |
|---------------|--------------------------|-------------------------------------------------|
| Deficient     |          < 50            | High risk for developing bone disease           |
|---------------|--------------------------|-------------------------------------------------|
| Insufficient  |          50-74           | Vitamin D concentration which normalizes        |
|               |                          | Parathyroid hormone concentration               |
|---------------|--------------------------|-------------------------------------------------|
| Sufficient    |          75-250          | Optimal concentration for maximal health benefit| 
|---------------|--------------------------|-------------------------------------------------|
| Potential     |          >250            | High risk for toxic effects                     |
| intoxication  |                          |                                                 |
 --------------------------------------------------------------------------------------------
Note  
·
The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
·
25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
·
Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
·
It shows seasonal variation, with values being 40-50% lower in winter than in summer. 
*WM17SPF*
Page 3 of 7
Sample Report
Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
:
LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, Sector 
18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report 
Test Name
Results
Units
Bio. Ref. Interval
·
Levels vary with age and are increased in pregnancy. 
·
A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available
THYROID PROFILE,TOTAL, SERUM
(CLIA)
1.00
T3, Total
 0.60 - 1.81 
ng/mL
7.00
T4, Total
 5.01 - 12.45 
µg/dL
3.00
TSH
 0.550 - 4.780 
µIU/mL
Note
1.
TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a 
minimum between 6-10 pm . The variation is of the order of 50% .  hence time of the day has 
influence on the measured serum TSH concentrations.
2.
Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or 
Total T4 levels especially in pregnancy and in patients on steroid therapy.
3.
Unbound fraction ( Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate 
more closely with clinical status of the patient than total T4/T3 concentration
4.
Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH   variant in 
some individuals
*WM17SPF*
Page 4 of 7
Sample Report
Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
: LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, 
Sector 18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report      
Test Name
Results
Units
Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD
(HPLC, NGSP certified)
HbA1c
%
4.00 - 5.60
10.0
Estimated average glucose (eAG)
mg/dL
240
Interpretation
HbA1c result is suggestive of  Diabetes/ Higher than glycemic goal in a known Diabetic patient. 
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, 
comorbid conditions, known CVD or advanced microvascular complications, hypoglycaemia unawareness, 
and individual patient considerations
Interpretation as per American Diabetes Association (ADA) Guidelines
 
 ------------------------------------------------------------------------------------------
| Reference Group | Non diabetic      | At risk       | Diagnosing  | Therapeutic goals    |
|                 | adults >=18 years | (Prediabetes) | Diabetes    | for glycemic control |
| ----------------|-------------------|---------------|-------------|----------------------|
| HbA1c in %      | 4.0-5.6           | 5.7-6.4       | >= 6.5      | <7.0                 |
 ------------------------------------------------------------------------------------------
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, 
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.
 ---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C    | FACTORS THAT AFFECT INTERPRETATION       |
| MEASUREMENT                          | OF HBA1C RESULTS                         |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal   | Any condition that shortens erythrocyte  |
| hemoglobin (HbF) and chemically      | survival or decreases mean erythrocyte   |
| modified derivatives of hemoglobin   | age (e.g.,recovery from acute blood loss,| 
| (e.g. carbamylated Hb in patients    | hemolytic anemia, HbSS, HbCC, and HbSC)  |
| with renal failure) can affect the   | will falsely lower HbA1c test results    |
| accuracy of HbA1c measurements       | regardless of the assay method used.Iron | 
|                                      | deficiency anemia is associated with     | 
|                                      | higher HbA1c                             |
 ---------------------------------------------------------------------------------
*WM17SPF*
Page 5 of 7
Sample Report
Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
:
LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, Sector 
18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report      
Test Name
Results
Units
Bio. Ref. Interval
COMPLETE BLOOD COUNT; CBC
Hemoglobin
(Photometry)
 13.00 - 17.00 
g/dL
15.00
Packed Cell Volume (PCV)
(Calculated)
 40.00 - 50.00 
%
45.00
RBC Count
(Electrical Impedence)
 4.50 - 5.50 
mill/mm3
5.00
MCV
(Electrical Impedence)
 83.00 - 101.00 
fL
100.00
MCH
(Calculated)
 27.00 - 32.00 
pg
30.00
MCHC
(Calculated)
 31.50 - 34.50 
g/dL
33.00
Red Cell Distribution Width (RDW)
(Electrical Impedence)
 11.60 - 14.00 
%
12.00
Total Leukocyte Count  (TLC)
(Electrical Impedence)
 4.00 - 10.00 
thou/mm3
5.00
Differential Leucocyte Count (DLC)
(VCS Technology)
 40.00 - 80.00 
Segmented Neutrophils
%
50.00
 20.00 - 40.00 
Lymphocytes
%
40.00
 2.00 - 10.00 
Monocytes
%
5.00
 1.00 - 6.00 
Eosinophils
%
4.00
 <2.00 
Basophils
%
1.00
Absolute Leucocyte Count
(Calculated)
 2.00 - 7.00 
Neutrophils
thou/mm3
2.50
 1.00 - 3.00 
Lymphocytes
thou/mm3
2.00
 0.20 - 1.00 
Monocytes
thou/mm3
0.25
 0.02 - 0.50 
Eosinophils
thou/mm3
0.20
 0.02 - 0.10 
Basophils
thou/mm3
0.05
Platelet Count
(Electrical impedence)
 150.00 - 410.00 
thou/mm3
151
Mean Platelet Volume
(Electrical Impedence)
 6.5 - 12.0 
fL
6.5
Note
1. As per the recommendation of International council for Standardization in Hematology, the differential
*WM17SPF*
Page 6 of 7
Sample Report
Report Status    
Male
25 Years
:
:
:
:
Age
Gender
Reported        
P
7/11/2023  11:08:00AM
SELF
WM17SPF
Mr.   DUMMY
:
:
:
:
:
Name        
Lab No.    
Ref By 
Collected       
A/c Status 
17/1/2024  10:55:48AM
Revised
Collected at            
:
Processed at             
:
LPL-ROHINI (NATIONAL REFERENCE LAB)
National Reference laboratory, Block E, Sector 
18, ROHINI
DELHI 110085
LPL-NATIONAL REFERENCE LAB
National Reference laboratory, Block E, 
Sector 18, Rohini, New Delhi -110085
Test Report      
Test Name
Results
Units
Bio. Ref. Interval
    leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of
    blood                      
2. Test conducted on EDTA whole blood
Dr Ajay Gupta
MD, Pathology
Technical Director - Hematology & 
Immunology                                      
NRL - Dr Lal PathLabs Ltd
Dr Gurleen Oberoi
DM(Hematopathology),                
MD,DNB,MNAMS
Senior Consultant and Lead- 
Hematopathology                             
NRL - Dr Lal PathLabs Ltd
Dr Himangshu Mazumdar
MD, Biochemistry
Sr. Consultant Biochemist                                               
NRL - Dr Lal PathLabs Ltd
Dr  Jatin Munjal
MD,Pathology
Consultant Pathologist                          
Dr Lal PathLabs Ltd
Dr Sarita Kumari Lal
MD, Pathology
Consultant Pathologist                          
Dr Lal PathLabs Ltd
Dr Sunanda
MD, Pathology
Sr. Consultant Pathologist - 
Hematology & Immunology                              
NRL - Dr Lal PathLabs Ltd
Dr Nimmi Kansal
MD, Biochemistry
Technical Director - Clinical Chemistry 
& Biochemical Genetics                    
NRL - Dr Lal PathLabs Ltd
Dr.Kamal Modi
MD, Biochemistry
Consultant Biochemist                                                   
NRL - Dr Lal PathLabs Ltd
This is a revised report & supersedes all the previously issued reports
AHEEEHAPMCIOAAMGABHMKINKAHPEFLFCNKKOAFPCJGCJOPAHEEEHA
BNFFFNBPAOFOFGEOACFDEDFHAHFHACEHMGIOEOJPMDAPNPBNFFFNB
GPFAACFPJNFNMACOFODKIGJOGABFDCIGKFPCBNFBOKKKMLECFGHOL
CJPHPNFBFNNAMGCGEAKLJLPGMPHELLIIKNGOFNMFOMCHFKNAFGFCG
OCPAHJFPNIBLHBDOGNKCFCIMCGHDCJKAOCNIBKOIKEDGHKFPGKPCH
HGNCLKFMEIMKBPEBALFCKKEGBGDDKECNOONFCCGJMLAAEMFEBIPKO
ICMCAHFHAFIKOJLMNCIPCKLIAHFHAKBEMLNCAKFFOKKFAHFHAKHHK
FGKPCDFGABGGDAGDHAPAHJPCGFEBFLBJPCECBNFFOBDGCCCFBHDDL
CFAGDIFKGPJLKMLNAMKAFPPDFEFFPHCDKKNKBMMBKNCIBACDIFHOC
MJDBGAFJKBJKNKMPBALJCFLDIPLCFHKHPFHNBDGPJNDPKBOIIEHCP
FMKBNJFMBIEAOIHLOIGDJEOKPLIFFNLHKFNCBIMNNKDOLFGIKKNNL
MNNFNNEHCEIPKKEAEMGAOKIDAHFHAFKHMKFGHLNPONKIAHFHACPPL
APBBBPAPBALONHHCOOIJFIELBCHDACAJOGMIBNNBOLCBCHHCFABAJ
HHHHHHHPHPHHHPHHPPHPPHPHHHPHPHHHPPPPHPPHPHHHPHPPHPHPP
IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted.ŸAll test results are dependent on the quality of the sample received by the Laboratory . 
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .ŸReport 
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost 
for 
derivation 
of 
exact 
value. 
Kindly 
submit 
request 
within 
72 hours 
post 
reporting.ŸTest 
results 
may 
show 
interlaboratory 
variations.ŸThe 
Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid 
for 
medico 
legal 
purposes.ŸThis 
is 
computer 
generated 
medical 
diagnostic 
report 
that 
has 
been 
validated 
by 
Authorized 
Medical 
Practitioner/Doctor.ŸThe report does not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action. 
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com 
National Reference lab, Delhi, a CAP (7171001) Accredited, ISO 9001:2015 (FS60411) & ISO 27001:2013 (616691) Certified laboratory.
*WM17SPF*
Page 7 of 7
Sample Report
